Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Query: "AREA[SponsorSearch](Inovio Pharmaceuticals)"
Count: 51
Selected: 0
NCT IDTitle
NCT04642638Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Healthy Seronegative Adults at High Risk of SARS-CoV-2 Exposure
NCT04588428Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers
NCT04398433INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP)
NCT04336410Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers
NCT04093076Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in Ghana
NCT03805984Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers
NCT03721978REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)
NCT03502785INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma
NCT03499795VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2
NCT03491683INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)
NCT03185013REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)
NCT03180684Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)
NCT02960594hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse
NCT02514213Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer
NCT02464670Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers
NCT02431312Phase I Study of INO-1800 With or Without INO-9112 + EP in Chronic Hepatitis B Subjects
NCT02241369Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and Malignancies
NCT02172911A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical Cancer
NCT02163057Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma
NCT01405885A Study of DNA Vaccine With Electroporation for the Prevention of Disease Caused by H1 and H5 Influenza Virus
NCT01403155A Follow-On Study With an H5 Influenza Vaccine for Subjects Who Participated in Study FLU-001
NCT01304524A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3
NCT01188850Fourth Dose of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + EP in Adult Females Previously Vaccinated With Three Doses of VGX-3100
NCT01142362Study of VGX-3400X, H5N1 Avian Influenza Virus DNA Plasmid + Electroporation in Healthy Adults
NCT01082692Study of PENNVAX™-B (Gag, Pol, Env) + Electroporation in HIV-1 Infected Adult Participants
NCT00685412Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3
NCT00198328Medpulser Electroporation With Bleomycin Study to Treat Posterior Head and Neck Squamous Cell Carcinoma
NCT00198315Medpulser Electroporation With Bleomycin Study to Treat Anterior Head and Neck Squamous Cell Carcinoma
NCT00198276Study Using the MedPulser Electroporation System With Bleomycin to Treat Cutaneous and Subcutaneous Cancer
NCT00198263Study Using the Medpulser Electroporation System With Bleomycin to Treat Head and Neck Cancer
NCT04367675INO 5401 Vaccination in BRCA1/2 Mutation Carriers
NCT03831503A Study of INO-A002 in Healthy Dengue Virus-naive Adults
NCT03674125Evaluation of Safety, Tolerability, and Immunogenicity Study of GLS-6150 in Healthy Volunteers and in Persons Previously Treated for Hepatitis C Virus Infection
NCT02887482Study of GLS-5700 in Dengue Virus Seropositive Adults
NCT02809443Study of GLS-5700 in Healthy Volunteers
NCT02772003DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection
NCT02027116Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of VGX-6150 for Second-line Therapy of Chronic Hepatitis C Infection
NCT01587131DNA-based Influenza Vaccine in the Elderly
NCT01335711CHRONVAC-C Study Followed by Standard of Care in Chronic Hepatitis C Virus (HCV) Subjects
NCT01184976Study Of VGX-3400, H5N1 Avian Flu Virus Plasmid DNA With Electroporation Device In Healthy Adult Males
NCT00563173Phase I/IIa Dose Ranging CHRONVAC-C® Study in Chronic HCV Patients
NCT03721718Evaluate the Safety, Tolerability and Immunogenicity Study of GLS-5300 in Healthy Volunteers
NCT02670187Phase I, Open Label Dose Ranging Safety Study of GLS-5300 in Healthy Volunteers
NCT02501278A Phase II Clinical Trial of Chemo-radiotherapy in Combination With INO-3112 in Patients With Locally Advanced Cervical Cancer
NCT04447781Safety, Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19
NCT00721461A Study to Test the Tolerability of an Investigational Electroporation Device in Healthy Adults (V930-001)
NCT04906629INO-4201 as Booster in Healthy VSV-ZEBOV Vaccinees
NCT03606213Therapeutic Vaccination in Treated HIV Disease
NCT01334060WT1 Immunity Via DNA Fusion Gene Vaccination in Haematological Malignancies by Intramuscular Injection Followed by Intramuscular Electroporation
NCT03835533Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations